Skip to content

Author

M. H. Diallo

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Multiregion profiling of genomic and transcriptional heterogeneity in head and neck squamous-cell carcinoma

This prospective multiregion study provides a comprehensive characterisation of genomic and tITH in localised HNSCC and suggests potential associations between heterogeneity, tumour biology, and clinical outcome that warrant validation in independent cohorts.

V. Heurtier, G. Marret, C. Lamy et al. · 0 citations
Open access Sep 2026

Efficacy and safety of pembrolizumab–lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program

Background Pembrolizumab–lenvatinib (P/L) is a standard option for patients with advanced or metastatic endometrial cancer (a/m EC) progressing after platinum-based chemotherapy, based on the KEYNOTE-775 trial. However, concerns remain regarding its real-world applicability, particularly in older, frailer patients and...

D. B. Roufai, L. Mansi, M. H. Diallo et al. · 0 citations
Open access Aug 2026

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

This study showed no OS gain in second-line treatment among patients pretreated with immunotherapy compared with those who received chemotherapy alone as first-line treatment.

E. Gobbini, M. H. Diallo, C. Clément-Duchêne et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.